NCT04868292已完成1 期
A Phase 1, Single-Center, Open-Label Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Intravenous Administration of SPR206 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Maximum observed concentration (Cmax) for ELF, AM, and plasma
研究概览
简要总结
To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of SPR206 in healthy adult volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Non-smoker for at least 12 months prior to screening for the study
- •BMI ≥ 18.5 and ≤ 32 (kg/m2) and weight between 55.0 and 100.0 kg (both inclusive)
- •Medically healthy without clinically significant abnormalities as assessed by the Investigator based on screening medical history, physical examination, vital signs, 12-lead ECG, hematology, biochemistry, coagulation, and urinalysis
- •Forced expiratory volume in 1 second (FEV1) of at least 80% of predicted value at screening
- •Ability and willingness to abstain from alcohol, caffeine, xanthine-containing beverages or food from 48 hours prior to study drug administration until discharge from the clinical unit
- •If male, must agree to use a condom and have a non-pregnant female partner of childbearing potential agree to use a highly effective method of contraception
- •If female, must be of non-childbearing potential or, if female of childbearing potential, a willingness to abstain from sexual activity or agree to use a high effective method of contraception that could lead to pregnancy
- •Other inclusion criteria per protocol
排除标准
- •History or presence of significant oncologic, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, vascular or neurological disease, including any acute illness or surgery within the past 3 months determined by the Investigator to be clinically relevant
- •Recent history (within 6 months) of known or suspected Clostridium difficile infection
- •History of seizure disorders
- •Positive urine drug, alcohol or cotinine testing at screening or check-in (Day -1)
- •Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HCV Ab)
- •Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening or prior to first dosing
- •Presence of the following symptoms at screening or within 28 days prior to screening or check-in (Day -1):
- •Fever, chills or sweats (temperature of 38 °C / 100.4 °F or higher)
- •Difficulty breathing
- •Sore throat
- •New or recent loss of taste or smell
- •Nausea, vomiting or diarrhea
- •Close contact with anyone who tested positive for SARS-CoV-2 infection within 28 days prior to screening or check-in (Day -1)
- •Electrocardiogram (ECG) with QTcF interval duration equal or greater than 450 msec for males and 470 msec for females
- •Subjects who have any of the following abnormalities on laboratory values at screening or Check-In including:
- •White blood cell count < 3,000/mm3, hemoglobin < 11g/dL
- •Absolute neutrophil count ≤ 2,000/mm3, platelet count <120,000/mm3
- •alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) greater than the upper limit of normal (ULN) for the reference laboratory
- •History of substance abuse or alcohol abuse
- •Use of prescription medicine & tobacco/nicotine or marijuana-containing products
- •A female who is pregnant or breastfeeding
- •Other exclusion criteria per protocol
研究组 & 干预措施
SPR206
Experimental
Healthy subjects meeting eligibility criteria will receive a total of three 100 mg SPR206 intravenous doses administered every 8 hours.
干预措施: SPR206 (Drug)
结局指标
主要结局
Maximum observed concentration (Cmax) for ELF, AM, and plasma
时间窗: 8 hours after the start of the third study drug IV infusion
Area under the concentration-time curve from time 0 to 8 hours (AUC0-8) for ELF, AM, and plasma
时间窗: 8 hours after the start of the third study drug IV infusion
Minimum concentration (Cmin) for ELF, AM, and plasma
时间窗: 8 hours after the start of the third study drug IV infusion
Time to the maximum observed concentration (Tmax) for ELF, AM, and plasma
时间窗: 8 hours after the start of the third study drug IV infusion
次要结局
- Incidence of abnormal safety laboratory assessments(Day -1 to Day 7)
- Incidence of abnormal vital sign assessments - respiratory rate(Day -1 to Day 7)
- Incidence of Treatment-Emergent Adverse Events(Day -1 to Day 7)
- Incidence of abnormal vital sign assessments - blood pressure(Day -1 to Day 7)
- Incidence of abnormal vital sign assessments - body temperature(Day -1 to Day 7)
- Incidence of abnormal vital sign assessments - heart rate(Day -1 to Day 7)
- Incidence of abnormal ECG assessments - PR, RR, QRS, QT and QTcF interval(Day -1 to Day 7)
- Incidence of abnormal physical exam assessments(Day -1 to Day 7)
- Incidence of abnormal ECG assessments - heart rate(Day -1 to Day 7)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.Healthy VolunteerNCT05955586Spero Therapeutics33
已完成
1 期
Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy SubjectsHealthy SubjectsNCT04951505Venatorx Pharmaceuticals, Inc.30
已完成
1 期
Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking VolunteersHealthy VolunteersNCT04710407Spero Therapeutics30
已完成
1 期
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy SubjectsHepatic ImpairmentNCT03369002CymaBay Therapeutics, Inc.32
已完成
1 期
Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human SubjectsIntrapulmonary Pharmacokinetics of WCK 2349NCT02253342Wockhardt30